Patient-Derived Xenograft Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Tumor Type (Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer), By Type (Mice, Rats), By End-User (Inpatient Settings, Community Settings) By Region and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 1.98 billion

CAGR (2023-2028)

9.97%

Fastest Growing Segment

Breast Cancer

Largest Market

North America


Market Overview

Global Patient-Derived Xenograft Model Market has valued at USD 1.98 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 9.97% through 2028. The Patient-Derived Xenograft (PDX) Model Market is experiencing a rapid expansion driven by its pivotal role in advancing cancer research and personalized medicine. PDX models, where human tumor tissues are implanted into immunodeficient mice, offer a sophisticated and clinically relevant platform for studying cancer biology and drug development.  Cancer research has come a long way in recent years, thanks to innovative techniques and models that help scientists understand disease better and develop more effective treatments. One such model gaining prominence in cancer research is the Patient-Derived Xenograft (PDX) model. PDX models are revolutionizing our approach to cancer studies, offering a more accurate representation of human tumors and enabling personalized medicine breakthroughs.

Patient-Derived Xenograft (PDX) models have gained immense popularity in the realm of preclinical research and drug development. These models, involving the transplantation of patient tumor tissue into immunodeficient mice, closely mimic the complexity of human tumors, offering invaluable insights into disease mechanisms and potential therapeutic strategies. A Patient-Derived Xenograft model involves implanting tumor tissue directly from a cancer patient into an immunodeficient mouse. This model faithfully recapitulates the tumor's genetic and molecular characteristics, as well as its growth patterns and response to therapies. By preserving the original tumor's heterogeneity and complexity, PDX models provide a reliable platform for investigating cancer biology, drug testing, and therapeutic development.  Firstly, the rising incidence of cancer worldwide has created an urgent need for more effective treatments. PDX models provide an invaluable tool for testing new cancer therapies, as they faithfully replicate the heterogeneity and complexity of human tumors, allowing researchers to assess drug efficacy and safety more accurately. Secondly, the era of personalized medicine has significantly contributed to the demand for PDX models. Tailoring treatments to individual patients based on their tumor's genetic and molecular characteristics has become a focal point in oncology. PDX models enable researchers and clinicians to predict a patient's response to specific therapies, paving the way for more targeted and effective treatment strategies.

Key Market Drivers

Rising Cancer Incidence and Unmet Medical Needs

One of the primary drivers behind the growth of the PDX model market is the global increase in cancer incidence. According to the World Cancer Research Fund, cancer is a leading cause of death worldwide, with new cases expected to rise by approximately 70% over the next two decades. This alarming trend has created an urgent need for more effective cancer treatments. PDX models, which faithfully replicate the complex and heterogeneous nature of human tumors, are instrumental in the development of novel therapies. They provide a platform for researchers to study various aspects of cancer, from tumor biology to drug response, ultimately contributing to the discovery of more effective treatment options. Cancer has long been one of the most significant global health challenges, with millions of lives affected each year. The Patient-Derived Xenograft model is a preclinical research tool that involves the implantation of human tumor tissues into immunodeficient mice. These mice then develop tumors that closely resemble the original human tumors in terms of genetic and molecular characteristics, heterogeneity, and growth patterns. PDX models offer several advantages over traditional cell line models, particularly in the context of rising cancer incidence and unmet medical needs. The global cancer incidence is increasing due to a number of factors, including aging populations, unhealthy lifestyles, and environmental pollution. PDX models maintain the complex mix of cell types found in patient tumors, making them an invaluable resource for studying tumor heterogeneity, disease progression, and the development of treatment resistance. This mirrors the clinical reality of cancer, where individual patients often have diverse tumor profiles.

Advancements in PDX Technology

Continuous advancements in PDX technology have significantly improved the reliability and versatility of these models. The development of patient-derived organoids, three-dimensional cell cultures that more accurately mimic human tumors, has expanded the range of applications for PDX models. Organoids can be used to study drug responses in a high-throughput manner and are particularly valuable for precision medicine efforts. Additionally, improvements in engraftment techniques have addressed some of the challenges associated with low engraftment rates, enhancing the overall utility of PDX models. As PDX technology continues to evolve, its attractiveness to researchers and industry stakeholders continues to grow.

Traditional PDX models required immediate transplantation of patient tumor tissue into mice. However, recent advancements in cryopreservation techniques have allowed for the long-term storage of patient-derived samples. This breakthrough not only facilitates easier logistics but also enables researchers to establish a repository of PDX models representing a wide range of cancer types and subtypes. Enhancements in engraftment techniques have increased the success rates of PDX model establishment. Researchers can now transplant smaller tissue samples with higher success rates, reducing the need for large amounts of patient material. This is particularly crucial when dealing with precious or limited biopsy samples. While traditional PDX models use immunocompromised mice, recent advances have led to the development of PDX models with humanized immune systems. These models offer a more accurate representation of the interactions between tumors and the human immune system, making them invaluable for immunotherapy research and development.

Biomarker Discovery and Drug Development

PDX models offer a unique opportunity for biomarker discovery, which is essential for developing targeted cancer therapies. Researchers can study the molecular and genetic profiles of PDX tumors to identify novel biomarkers associated with drug response and resistance. This knowledge is invaluable for designing more effective, targeted therapies that improve patient outcomes. Biomarker-driven drug development is gaining momentum, and PDX models are at the forefront of these efforts. The patient-derived xenograft (PDX) model is a powerful tool for cancer research and drug development. PDX models are created by transplanting tumor cells from a patient into a mouse or other animal. This allows researchers to study the tumor in a more natural environment and to test new drugs in a more relevant setting than traditional in vitro models. PDX models are increasingly being used to discover and validate biomarkers for cancer. Biomarkers are biological molecules that can be used to identify, diagnose, or monitor a disease. PDX models can be used to identify biomarkers that are specific to a particular cancer type or that are predictive of patient response to treatment. PDX models are also being used to develop new drugs for cancer. PDX models can be used to screen new drugs for efficacy and safety. They can also be used to study the mechanisms of action of drugs and to identify drug combinations that are more effective than single drugs.

One of the most significant driving forces behind the surge in PDX model adoption is its ability to facilitate biomarker discovery. Biomarkers are measurable biological indicators that provide critical information about disease progression, response to therapy, and prognosis. Identifying and validating biomarkers is crucial in understanding disease mechanisms and tailoring treatments to individual patients. PDX models offer a unique advantage in this context as they closely replicate the molecular and cellular characteristics of human tumors, enabling researchers to study disease pathways, genetic mutations, and protein expressions within an in vivo setting.

 

Download Free Sample Report

Key Market Challenges

Heterogeneity and Variability

One of the primary challenges with PDX models is the inherent heterogeneity and variability of human tumors. Human cancers are highly diverse, even within the same cancer type, making it difficult to create PDX models that accurately represent all aspects of the disease. Tumor heterogeneity can result in variations in drug responses, making it challenging to predict the effectiveness of therapies based on PDX models alone. This limitation can hinder the translatability of preclinical results to clinical outcomes. Human cancers are notorious for their diversity, even among tumors of the same type or subtype. This diversity arises from variations in genetic mutations, cellular composition, microenvironmental factors, and many other intricate biological aspects. As a result, creating PDX models that faithfully represent the entirety of this heterogeneity becomes a formidable task. The challenge lies in selecting a small piece of tumor tissue from a patient, engrafting it into immunodeficient mice, and expecting it to accurately mirror the complexity of the original tumor. While PDX models do capture many aspects of this diversity, they cannot fully replicate the full spectrum of genetic mutations and cellular interactions that occur within a patient's tumor.

Time and Resource Intensity

The generation and maintenance of PDX models are time-consuming and resource-intensive processes. It can take several months to establish a single PDX model, including the initial engraftment, expansion, and characterization phases. Furthermore, PDX models require continuous monitoring and care, adding to the operational costs. This time and resource intensity can limit the scalability of PDX model studies, especially for academic and smaller research institutions with limited budgets and resources. Establishing and maintaining PDX models is a laborious and time-consuming process. It typically begins with the transplantation of patient tumor tissue into immunodeficient mice. While this initial engraftment phase can take several weeks, it represents only the beginning of a prolonged journey. PDX models require continuous monitoring, including tracking tumor growth, evaluating treatment responses, and managing the health and well-being of the mice. This ongoing care and oversight add to the operational costs and consume valuable researcher time.

Costs and Accessibility

Establishing and maintaining PDX models can be expensive, particularly for institutions with limited budgets. The costs associated with acquiring immunodeficient mice, housing and caring for them, and conducting experiments can be a barrier to entry for many researchers. Furthermore, the need for specialized equipment and expertise in handling PDX models adds to the overall costs. The high upfront investment and ongoing expenses can limit the accessibility of PDX models to a broader research community. Creating and maintaining PDX models is an expensive endeavor. It encompasses several costly components, including acquiring immunodeficient mice, housing and caring for them in controlled environments, procuring patient tumor samples, and conducting experiments. The upfront investment and ongoing operational expenses can place PDX models out of reach for many academic institutions, smaller research organizations, and emerging biotech companies with constrained budgets. The high costs associated with PDX models create a disparity in accessibility, limiting their availability primarily to well-funded research institutions and large pharmaceutical companies.

Key Market Trends

Rising Interest in Personalized Medicine

Personalized medicine, which tailors medical treatments to individual patients based on their genetic makeup and specific disease characteristics, is gaining momentum. PDX models play a pivotal role in this paradigm shift by offering a platform for testing therapies on patient-specific tumor samples. The ability to create "avatar mice" with tumors derived from individual patients allows for more accurate prediction of treatment responses, reducing the risk of adverse reactions and optimizing therapeutic outcomes. PDX models are uniquely suited to support the principles of personalized medicine. By transplanting patient tumor tissue directly into immunodeficient mice, researchers can create "avatar mice" that carry tumors derived from individual patients. These models faithfully replicate the genetic and molecular complexity of the original tumors, allowing for highly personalized preclinical testing of potential therapies. As a result, PDX models enable researchers to predict how an individual patient's tumor will respond to specific treatments, paving the way for more effective and targeted therapies.

The benefits of personalized medicine are manifold. Patients stand to gain from treatments that are not only more effective but also less likely to produce adverse side effects, as therapies can be tailored to their genetic and molecular profiles. Pharmaceutical companies benefit by increasing the success rates of clinical trials and reducing the costly late-stage failures that have plagued drug development historically.

Advances in Genomic Profiling

Genomic sequencing technologies have advanced at an astonishing pace, enabling researchers to delve deeper into the genetic and molecular underpinnings of tumors. This wealth of genomic data is being integrated into PDX model studies, allowing for a more comprehensive understanding of the genetic mutations, biomarkers, and pathways driving cancer. This integration enhances the utility of PDX models in drug development by facilitating the identification of potential therapeutic targets and predictive biomarkers. Moreover, genomic profiling has opened the door to the identification of specific biomarkers and therapeutic targets that can guide drug development. PDX models, when integrated with genomics, become powerful tools for validating these targets and predicting patient responses to novel treatments. This predictive capability is essential for reducing the attrition rates of drug candidates during clinical trials and ensuring that the right therapies reach the right patients.

Immunotherapy Revolution

Immunotherapy has emerged as a groundbreaking approach in the treatment of cancer and other diseases. PDX models are instrumental in studying the complex interactions between tumors and the immune system. Researchers are using these models to assess the efficacy of immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, and to explore novel combination therapies. PDX models are thus playing a pivotal role in advancing the field of immunotherapy. PDX models offer a unique advantage in studying immunotherapies because they closely mimic the in vivo tumor microenvironment, including the intricate interplay between tumor cells and immune cells. Researchers can use these models to assess the effectiveness of immunotherapies in a setting that faithfully replicates the complexity of human tumors. This capability is critical for optimizing immunotherapeutic strategies, predicting patient responses, and identifying potential biomarkers of immunotherapy success. One of the key factors driving the adoption of PDX models in immunotherapy research is their ability to create personalized models. Researchers can generate PDX models using patient-specific tumor samples, allowing them to test immunotherapies on tumors that closely resemble those of individual patients.

Segmental Insights

Tumor Type Insights

Based on the tumor types, the breast cancer segment emerged as the dominant player in the global market for Patient-Derived Xenograft Model in 2022.This is attributed to increasing breast cancer cases across the world. First and foremost, breast cancer is one of the most prevalent cancers worldwide, affecting millions of individuals each year. Its high incidence has made it a priority for research and drug development efforts, driving significant investments into understanding its complexities and identifying effective treatments. PDX models have proven to be particularly valuable in breast cancer research due to their ability to faithfully replicate the genetic and molecular characteristics of patient tumors. Researchers can use these models to study the heterogeneity of breast cancer subtypes and test potential therapies tailored to individual patients.

Model Type Insights

Based on the model type, the mice model segment emerged as the dominant player in the global market for Patient-Derived Xenograft Model in 2022. This is attributed to several key factors including Biological Relevance, Mice models have a well-established infrastructure, and mice models enable researchers to conduct longitudinal studies over an extended period, etc. Mice models closely mimic the physiological and biological aspects of human tumors, making them a preferred choice for PDX studies. The engraftment of patient tumor tissue into immunodeficient mice allows researchers to recreate the tumor microenvironment, including interactions with immune cells, stromal components, and blood vessels. This biological relevance is essential for studying disease progression and evaluating the efficacy of potential therapies.

 

Download Free Sample Report

Regional Insights

North America emerged as the dominant player in the global Patient-Derived Xenograft Model market in 2022, holding the largest market share. This is on account of several key factors such as advanced healthcare infrastructure, Strong Research and Development Ecosystem and high regulatory acceptance. North America has a relatively high incidence of various diseases, including cancer, which necessitates intensive research efforts and the development of more effective therapies. PDX models have found particular relevance in oncology research, aligning with the region's focus on cancer treatment and drug discovery.

North America boasts one of the most advanced healthcare infrastructures globally, with state-of-the-art hospitals, medical facilities, and research institutions. This robust healthcare ecosystem facilitates the diagnosis and treatment of conditions that require HGH therapy, contributing to the region's prominence in the market.

Recent Developments

  • In December 2020, Collagen Matrix, Inc., a leader in collagen-based, regenerative, xenograft-derived medical devices, and Linden Capital Partners ("Linden") announced the acquisition of Sunstar's Degradable Solutions . It includes the GUIDOR brand of synthetic, biodegradable medical implants. The goal of the acquisition is to increase the variety of technologies offered to clients.
  • In April 2020, Crown Bioscience Inc. acquired unique models from Leading Academic Medical Centres and entered into partnerships with the University of Washington and the Dana-Farber Cancer Institute. Both the company's product expansion and the community working on oncology drugs benefit from this.

Key Market Players

  • Charles River Laboratories Inc.
  • The Jackson Laboratory
  • Crown Bioscience,Inc.
  • Altogen Labs
  • Envigo
  • WuxiAppTec
  • Oncodesign
  • Hera BioLabs
  • XenTech
  • Abnova Corporation

 By Tumor Type

By End User

By Type

By Region
  • Lung Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Breast Cancer
  • Other Cancer
  • Inpatient Settings
  • Community Settings
  • Rats
  • Mice
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Patient-Derived Xenograft Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Patient-Derived Xenograft Model Market, By Tumor Type:

o   Lung Cancer

o   Pancreatic Cancer

o   Prostate Cancer

o   Breast Cancer

o   Other Cancer

  • Patient-Derived Xenograft Model Market, By End User:

o   Inpatient Settings

o   Community Settings

  • Patient-Derived Xenograft Model Market, By Type:

o   Rats

o   Mice

  • Patient-Derived Xenograft Model Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

§  Turkey

§  Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Patient-Derived Xenograft Model Market.

Available Customizations:

Global Patient-Derived Xenograft Model market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Patient-Derived Xenograft Model Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Patient-Derived Xenograft Model Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Tumor Type (Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer)

5.2.2.    By Type (Mice, Rats)

5.2.3.    By End-User (Inpatient Settings, Community Settings)

5.2.4.    By Company (2022)

5.2.5.    By Region

5.3.  Market Map

6.    North America Patient-Derived Xenograft Model Market Outlook

6.1.  Market Size & Forecast

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Tumor Type  

6.2.2.    By Type  

6.2.3.    By End-user

6.2.4.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States Patient-Derived Xenograft Model Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.            By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.            By Tumor Type    

6.3.1.2.2.            By Type

6.3.1.2.3.            By End-user

6.3.2.    Mexico Patient-Derived Xenograft Model Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.            By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.            By Tumor Type 

6.3.2.2.2.            By Type

6.3.2.2.3.            By End-user

6.3.3.    Canada Patient-Derived Xenograft Model Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.            By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.            By Tumor Type   

6.3.3.2.2.            By Type

6.3.3.2.3.            By End-user

7.    Europe Patient-Derived Xenograft Model Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Tumor Type     

7.2.2.    By Type  

7.2.3.    By End-user

7.2.4.    By Country

7.3.  Europe: Country Analysis

7.3.1.    France Patient-Derived Xenograft Model Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.            By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.            By Tumor Type

7.3.1.2.2.            By Type

7.3.1.2.3.            By End-user

7.3.2.    Germany Patient-Derived Xenograft Model Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.            By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.            By Tumor Type  

7.3.2.2.2.            By Type

7.3.2.2.3.            By End-user

7.3.3.    United Kingdom Patient-Derived Xenograft Model Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.            By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.            By Tumor Type   

7.3.3.2.2.            By Type

7.3.3.2.3.            By End-user

7.3.4.    Italy Patient-Derived Xenograft Model Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.            By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.            By Tumor Type

7.3.4.2.2.            By Type

7.3.4.2.3.            By End-user

7.3.5.    Spain Patient-Derived Xenograft Model Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.            By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.            By Tumor Type

7.3.5.2.2.            By Type

7.3.5.2.3.            By End-user

8.    Asia-Pacific Patient-Derived Xenograft Model Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Tumor Type 

8.2.2.    By Type  

8.2.3.    By End-user

8.2.4.    By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.    China Patient-Derived Xenograft Model Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.            By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.            By Tumor Type

8.3.1.2.2.            By Type

8.3.1.2.3.            By End-user

8.3.2.    India Patient-Derived Xenograft Model Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.            By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.            By Tumor Type     

8.3.2.2.2.            By Type

8.3.2.2.3.            By End-user

8.3.3.    South Korea Patient-Derived Xenograft Model Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.            By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.            By Tumor Type     

8.3.3.2.2.            By Type

8.3.3.2.3.            By End-user

8.3.4.    Japan Patient-Derived Xenograft Model Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.            By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.            By Tumor Type     

8.3.4.2.2.            By Type

8.3.4.2.3.            By End-user

8.3.5.    Australia Patient-Derived Xenograft Model Market Outlook

8.3.5.1.        Market Size & Forecast

8.3.5.1.1.            By Value

8.3.5.2.        Market Share & Forecast

8.3.5.2.1.            By Tumor Type     

8.3.5.2.2.            By Type

8.3.5.2.3.            By End-user

9.    South America Patient-Derived Xenograft Model Market Outlook

9.1.  Market Size & Forecast

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Tumor Type  

9.2.2.    By Type  

9.2.3.    By End-user

9.2.4.    By Country

9.3.  South America: Country Analysis

9.3.1.    Brazil Patient-Derived Xenograft Model Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.            By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.            By Tumor Type     

9.3.1.2.2.            By Type

9.3.1.2.3.            By End-user

9.3.2.    Argentina Patient-Derived Xenograft Model Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.            By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.            By Tumor Type     

9.3.2.2.2.            By Type

9.3.2.2.3.            By End-user

9.3.3.    Colombia Patient-Derived Xenograft Model Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.            By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.            By Tumor Type     

9.3.3.2.2.            By Type

9.3.3.2.3.            By End-user

10.  Middle East and Africa Patient-Derived Xenograft Model Market Outlook

10.1.   Market Size & Forecast         

10.1.1. By Value

10.2.   Market Share & Forecast

10.2.1. By Tumor Type    

10.2.2. By Type  

10.2.3. By End-user

10.2.4. By Country

10.3.   MEA: Country Analysis

10.3.1. South Africa Patient-Derived Xenograft Model Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Tumor Type     

10.3.1.2.2.         By Type

10.3.1.2.3.         By End-user

10.3.2. Saudi Arabia Patient-Derived Xenograft Model Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Tumor Type     

10.3.2.2.2.         By Type

10.3.2.2.3.         By End-user

10.3.3. UAE Patient-Derived Xenograft Model Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Tumor Type     

10.3.3.2.2.         By Type

10.3.3.2.3.         By End-user

11.  Market Dynamics

11.1.   Drivers

11.2.   Challenges

12.  Market Trends & Developments

12.1.   Recent Developments

12.2.   Product Launches

12.3.   Mergers & Acquisitions

13.  PESTLE Analysis

14.  Porter’s Five Forces Analysis

14.1.   Competition in the Industry

14.2.   Potential of New Entrants

14.3.   Power of Suppliers

14.4.   Power of Customers

14.5.   Threat of Substitute Product

15.  Competitive Landscape

15.1.   Business Overview

15.2.   Company Snapshot

15.3.   Products & Services

15.4.   Financials (In case of listed companies)

15.5.   Recent Developments

15.6.   SWOT Analysis

15.6.1. Charles River Laboratories Inc.

15.6.2. The Jackson Laboratory

15.6.3. Crown Bioscience,Inc.

15.6.4. Altogen Labs

15.6.5. Envigo

15.6.6. WuxiAppTec

15.6.7. Oncodesign

15.6.8. Hera BioLabs

15.6.9. XenTech

15.6.10.               Abnova Corporation

16. Strategic Recommendation

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Patient-Derived Xenograft Model Market was estimated to be USD 1.98 billion in 2022.

down-arrow

Charles River Laboratories Inc.,The Jackson Laboratory, Crown Bioscience,Inc., Altogen Labs, Envigo, WuxiAppTec, Oncodesign, Hera BioLabs, XenTech, Abnova Corporation, etc. are some of the key players operating in the Global Patient-Derived Xenograft Model Market.

down-arrow

Standardization of protocols and the need for reducing the time and cost associated with PDX model generation, addressing the ethical and regulatory considerations surrounding the use of animals in PDX models signify a major challenge for the Global Patient-Derived Xenograft Model market.

down-arrow

Increasing demand for personalized medicine and the pivotal role of PDX models in mimicking the complexity of human tumors, as well as the rising interest in immunotherapy and genomic profiling, are factors which boost the demand for Patient-Derived Xenograft Model for monitoring and managing health conditions.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Patient-Derived Xenograft Model Market to Grow with a CAGR of 9.97% through 2028

Sep, 2023

Rising interest in immunotherapy and genomic profiling is expected to drive the Global Patient-Derived Xenograft Model Market growth in the forecast period, 2024-2028.

Why Choose Us